2020 American Transplant Congress
Efficacy Of CMV Prophylaxis In Liver Transplant Recipients
Intermountain Medical Center, Murray, UT
*Purpose: Human cytomegalovirus (CMV) is a ubiquitous beta herpesvirus present in the human population at rates between 30% and 90%. It can be transmitted via…2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…2020 American Transplant Congress
Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation
Duke University Medical Center, Durham, NC
*Purpose: Cytomegalovirus (CMV) commonly affects thoracic solid organ transplant (SOT) recipients, and standard antiviral therapies are limited by myelosuppression, renal dysfunction, and emergence of resistance.…2020 American Transplant Congress
A Comprehensive Evaluation of Risk Factors for Pneumocystis Jiroveci Pneumonia in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
*Purpose: Pneumocytis jiroveci pneumonia (PJP) is an important opportunistic fungal infection in solid organ transplant (SOT) recipients that carries a significant morbidity and mortality. Several…2020 American Transplant Congress
Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients
*Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…2020 American Transplant Congress
Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients
*Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…2020 American Transplant Congress
Comparison of Prophylaxis Strategies for CMV Infection in Liver Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: The best strategy to prevent cytomegalovirus (CMV) following liver transplantation is not defined for intermediate risk recipients (recipient seropositive (R+) regardless of donor status).…2020 American Transplant Congress
Epidemiology Cytomegalovirus Infection/Disease in Kidney Transplant Recipients: A Systematic Review of Observational Studies
1Merck & Co., Inc., Kenilworth, NJ, 2Evidera, Inc., Waltham, MA, 3Tufts Medical Center, Boston, MA
*Purpose: Efficacy of several CMV anti-viral strategies has been shown in controlled trials for CMV infection/disease in kidney transplant recipients (KTRs). However, a comprehensive analysis…2019 American Transplant Congress
More Advanced Heart Failure Prior To Transplant May Influence The Cytomegalovirus Specific T Cell Response In Cytomegalovirus Positive Recipients.
Bellvitge Universitary Hospital, L' Hospitalet de Llobregat, Spain
*Purpose: Current assessment of risk of Cytomegalovirus (CMV) infection in CMV+ heart transplant (HT) recipients is poor. A diminished CMV-specific T cell response against 2…2019 American Transplant Congress
CMV-Specific Cell-Mediated Immunity Early after Transplantation Discriminates R+ Transplant Patients at Risk of CMV Infection among Different Solid Organ Transplants
*Purpose: While monitoring CMV-specific cell-mediated immunity(CMI) has shown to be effective in predicting the risk of CMV infection, comparisons across different solid organ transplants(SOT) and…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 33
- Next Page »